Drugs / 64Cu-SAR-bisPSMA
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04839367 | Jul 2021 → Oct 2022 | prostate neoplasm | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05249127 | Apr 2022 → Aug 2023 | prostate cancer | Clarity Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT04868604 | Aug 2021 → Sep 2026 overdue | castration-resistant prostate carcinoma | Clarity Pharmaceuticals Ltd | Recruiting | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT06907641 | Nov 2024 → Nov 2025 overdue | cancer | St Vincent's Hospital, Sydney | Recruiting | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT06970847 | May 2025 → Dec 2026 expected | prostate cancer | Clarity Pharmaceuticals Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06056830 | Dec 2023 → Sep 2026 overdue | prostate cancer | Clarity Pharmaceuticals Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-SAR-bisPSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05249127 ↗ |
| Known as | 64Cu-bisPSMA | “64Cu-SAR-bisPSMA PET/computed tomography (CT) (64Cu-bisPSMA) is a bivalent-PSMA-peptide with 12.7-hr half-life.” PMID 41904043 ↗ Mar 2026 |
| Modality | Diagnostic / imaging agent | “64 Cu-SAR-bisPSMA as an imaging agent for PC.” PMID 42395167 ↗ Jun 2026 |
| Route | Intravenous | “an intravenous injection of 64 Cu-SAR-bisPSMA” PMID 42395167 ↗ Jun 2026 |